Distribution of High-Risk Human Papillomavirus Genotypes among HIV-Negative Women with and without Cervical Intraepithelial Neoplasia in South Africa

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  McDonald, Alicia C ^a   Denny, Lynette ^b   Wang, Chunhui ^c   Tsai, Wei Yann ^a   Wright, Thomas C ^c   Kuhn, Louise ^a,d  

^a Department of Medicine   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Mailman School of Public Health ^*  (United States)

^d Vagelos College of Physicians and Surgeons   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER GRADING; COLPOSCOPY; CONTROLLED STUDY; DNA DETERMINATION; ENDOCERVICAL CURETTAGE; FEMALE; GENOTYPE; GYNECOLOGICAL EXAMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 35; INFECTION RISK; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; SOUTH AFRICA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84866131374     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044332     Document Type: Article

References (38)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S, (2007) Human papillomavirus and cervical cancer. Lancet 370: 890-907.
2. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127: 2893-2917.
3. IARC (2007) IARC Monograph on the Evaluation of Carcinogenic Risks to Human, Volume 90, Human papillomaviruses. Lyon.
4. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, et al. (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International Journal of Cancer 121: 621-632.
5. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncology 11: 1048-1056.
6. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-1765.
7. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology 6: 271-278.
8. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, et al. (2011) High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 135: 468-475.
9. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, et al. (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. Journal of Infectious Diseases 202: 1789-1799.
10. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, et al. (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998.
11. Parkin DM, Bray F, (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24Suppl 3: S3/11-25.
12. Ferlay J, Shin H, Bray F, Forman D, Mathers C, et al. (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer.
13. Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, et al. (2005) Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 294: 2173-2181.
14. Denny L, Kuhn L, Pollack A, Wright TC Jr, Denny L, et al. (2002) Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer 94: 1699-1707.
15. Coutlee F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, et al. (2006) Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. Journal of Clinical Microbiology 44: 1998-2006.
16. Ortiz M, Torres M, Munoz L, Fernandez-Garcia E, Canals J, et al. (2006) Oncogenic human papillomavirus (HPV) type distribution and HPV type 16 E6 variants in two Spanish population groups with different levels of HPV infection risk. Journal of Clinical Microbiology 44: 1428-1434.
17. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, et al. (2003) Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. Journal of the National Cancer Institute 95: 46-52.
18. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, et al. (2008) Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. International Journal of Cancer 123: 1864-1870.
19. Serwadda D, Wawer MJ, Shah KV, Sewankambo NK, Daniel R, et al. (1999) Use of a hybrid capture assay of self-collected vaginal swabs in rural Uganda for detection of human papillomavirus. Journal of Infectious Diseases 180: 1316-1319.
20. Womack SD, Chirenje ZM, Gaffikin L, Blumenthal PD, McGrath JA, et al. (2000) HPV-based cervical cancer screening in a population at high risk for HIV infection. International Journal of Cancer 85: 206-210.
21. Steben M, Duarte-Franco E, Steben M, Duarte-Franco E, (2007) Human papillomavirus infection: epidemiology and pathophysiology. Gynecologic Oncology 107: S2-5.
22. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD, (1998) Natural history of cervicovaginal papillomavirus infection in young women. New England Journal of Medicine 338: 423-428.
23. Zhang Q, Kuhn L, Denny LA, De Souza M, Taylor S, et al. (2007) Impact of utilizing p16INK4A immunohistochemistry on estimated performance of three cervical cancer screening tests. International Journal of Cancer 120: 351-356.
24. Stoler MH, Wright TC Jr, Sharma A, Zhang G, Apple R, et al. (2012) The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study. Am J Clin Pathol 137: 295-303.
25. Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L, (2009) Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. Journal of Medical Virology 81: 529-535.
26. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, et al. (2005) A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. Journal of Infectious Diseases 191: 1808-1816.
27. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, et al. (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. The Lancet Infectious Diseases 7: 453-459.
28. Allan B, Marais DJ, Hoffman M, Shapiro S, Williamson AL, et al. (2008) Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies. Journal of Clinical Microbiology 46: 740-742.
29. Said HM, Ahmed K, Burnett R, Allan BR, Williamson AL, et al. (2009) HPV genotypes in women with squamous intraepithelial lesions and normal cervixes participating in a community-based microbicide study in Pretoria, South Africa. Journal of Clinical Virology 44: 318-321.
30. De Vuyst H, Steyaert S, Van Renterghem L, Claeys P, Muchiri L, et al. (2003) Distribution of human papillomavirus in a family planning population in nairobi, kenya. Sexually Transmitted Diseases 30: 137-142.
31. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, et al. (2004) Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. British Journal of Cancer 90: 638-645.
32. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. Journal of Infectious Diseases 199: 926-935.
33. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314.
34. Jeronimo J, Massad LS, Schiffman M (2007) Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol 197: 47 e41-48.
35. Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM, (2011) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. International Journal of Cancer 128: 927-935.
36. Hamlin-Douglas LK, Coutlee F, Roger M, Franco EL, Brassard P, (2008) Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiology, Biomarkers & Prevention 17: 3141-3149.
37. Cox JT, Cox JT, (2006) The development of cervical cancer and its precursors: what is the role of human papillomavirus infection? Current Opinion in Obstetrics & Gynecology 18Suppl 1: s5-s13.
38. Castle PE, Gutierrez EC, Leitch SV, Maus CE, McMillian RA, et al. (2011) Evaluation of a new DNA test for detection of carcinogenic human papillomavirus. J Clin Microbiol 49: 3029-3032.